[S-methyl-11C](±)-7-methoxy-3-(4-(4-(methylthio)phenyl)butyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol (11C-NR2B-SMe) and its enantiomers were synthesized as candidates for imaging the NR2B subunit within the N-methyl-d-aspartate receptor with PET. Methods: Brains were scanned with PET for 90 min after intravenous injection of one of the candidate radioligands into rats. To detect any NR2B-specific binding of radioligand in brain, various preblocking or displacing agents were evaluated for their impact on the PET brain imaging data. Radiometabolites from brain and other tissues were measured ex vivo and in vitro. Results: Each radioligand gave high early whole-brain uptake of radioactivity, followed by a brief fast decline and then a slow final decline. 11C-(S)-NR2B-SMe was studied extensively. Ex vivo measurements showed that radioactivity in rat brain at 30 min after radioligand injection was virtually unchanged radioligand. Only less lipophilic radiometabolites appeared in plasma. High-affinity NR2B ligands, Ro-25-6981, ifenprodil, and CO101244, showed increasing preblocking of whole-brain radioactivity retention with increasing dose (0.01-3.00 mg/kg, intravenously). Five σ1 antagonists (FTC146, BD1407, F3, F4, and NE100) and 4 σ1 agonists ((+)-pentazocine, (±)-PPCC, PRE-084, and (+)-SKF10047) were ineffective preblocking agents, except FTC146 and F4 at a high dose. Two potent σ1 receptor agonists, TC1 and SA4503, showed dose-dependent preblocking effects in the presence or absence of pharmacologic σ1 receptor blockade with FTC146. Conclusion: 11C-(S)-NR2B-SMe has adequate NR2B-specific PET signal in rat brain to warrant further evaluation in higher species. TC1 and SA4503 likely have off-target binding to NR2B in vivo.
[S-methyl-11C](±)-7-methoxy-3-(4-(4-(methylthio)phenyl)butyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol (11C-NR2B-SMe) and its enantiomers were synthesized as candidates for imaging the NR2B subunit within the N-methyl-d-aspartate receptor with PET. Methods: Brains were scanned with PET for 90 min after intravenous injection of one of the candidate radioligands into rats. To detect any NR2B-specific binding of radioligand in brain, various preblocking or displacing agents were evaluated for their impact on the PET brain imaging data. Radiometabolites from brain and other tissues were measured ex vivo and in vitro. Results: Each radioligand gave high early whole-brain uptake of radioactivity, followed by a brief fast decline and then a slow final decline. 11C-(S)-NR2B-SMe was studied extensively. Ex vivo measurements showed that radioactivity in rat brain at 30 min after radioligand injection was virtually unchanged radioligand. Only less lipophilic radiometabolites appeared in plasma. High-affinity NR2B ligands, Ro-25-6981, ifenprodil, and CO101244, showed increasing preblocking of whole-brain radioactivity retention with increasing dose (0.01-3.00 mg/kg, intravenously). Five σ1 antagonists (FTC146, BD1407, F3, F4, and NE100) and 4 σ1 agonists ((+)-pentazocine, (±)-PPCC, PRE-084, and (+)-SKF10047) were ineffective preblocking agents, except FTC146 and F4 at a high dose. Two potent σ1 receptor agonists, TC1 and SA4503, showed dose-dependent preblocking effects in the presence or absence of pharmacologic σ1 receptor blockade with FTC146. Conclusion: 11C-(S)-NR2B-SMe has adequate NR2B-specific PET signal in rat brain to warrant further evaluation in higher species. TC1 and SA4503 likely have off-target binding to NR2B in vivo.
Authors: Xiang Liu; Samuel D Banister; MacDonald J Christie; Richard Banati; Steve Meikle; Mark J Coster; Michael Kassiou Journal: Eur J Pharmacol Date: 2006-10-18 Impact factor: 4.432
Authors: P Avenet; J Léonardon; F Besnard; D Graham; J Frost; H Depoortere; S Z Langer; B Scatton Journal: Eur J Pharmacol Date: 1996-01-25 Impact factor: 4.432
Authors: Faraz Kazmi; Tiffini Hensley; Chad Pope; Ryan S Funk; Greg J Loewen; David B Buckley; Andrew Parkinson Journal: Drug Metab Dispos Date: 2013-02-01 Impact factor: 3.922
Authors: Ahmed Haider; Adrienne Müller Herde; Stefanie D Krämer; Jasmine Varisco; Claudia Keller; Katrin Frauenknecht; Yves P Auberson; Louisa Temme; Dina Robaa; Wolfgang Sippl; Roger Schibli; Bernhard Wünsch; Linjing Mu; Simon M Ametamey Journal: J Nucl Med Date: 2019-01-25 Impact factor: 10.057
Authors: Csaba Lengyel; László Dézsi; Péter Biliczki; Csilla Horváth; László Virág; Norbert Iost; Miklós Németh; László Tálosi; Julius Gy Papp; András Varró Journal: Br J Pharmacol Date: 2004-08-09 Impact factor: 8.739
Authors: Stefanie D Krämer; Thomas Betzel; Linjing Mu; Ahmed Haider; Adrienne Müller Herde; Anna K Boninsegni; Claudia Keller; Marina Szermerski; Roger Schibli; Bernhard Wünsch; Simon M Ametamey Journal: J Nucl Med Date: 2017-11-30 Impact factor: 10.057
Authors: Kelly Smart; Ming-Qiang Zheng; Hazem Ahmed; Hanyi Fang; Yuping Xu; Lisheng Cai; Daniel Holden; Michael Kapinos; Ahmed Haider; Zachary Felchner; Jim R Ropchan; Gilles Tamagnan; Robert B Innis; Victor W Pike; Simon M Ametamey; Yiyun Huang; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2022-02-25 Impact factor: 6.960
Authors: MingQiang Zheng; Hazem Ahmed; Kelly Smart; Yuping Xu; Daniel Holden; Michael Kapinos; Zachary Felchner; Ahmed Haider; Gilles Tamagnan; Richard E Carson; Yiyun Huang; Simon M Ametamey Journal: Eur J Nucl Med Mol Imaging Date: 2022-02-02 Impact factor: 10.057